

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711 F: 844.513.1522

W: fresenius-kabi.ca

September 18, 2025

Acyclovir Sodium Injection 50 mg/mL, 20 mL Vial Backorder Notification

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due an increase in demand from a market shortage, we will be encountering a supply interruption on our **Acyclovir Sodium Injection 50 mg/mL**, **20 mL Vial** effective **September 18**, **2025**, until **December 19**, **2025**.

DIN	Fresenius Kabi Product Code	NEW! MSD Product Code	McKesson Product Code	Product Description	Estimated Stockout Date*	Estimated Availability Date
02236926	C302520	1000503	177071	Acyclovir Sodium Injection 50 mg/mL, 20 mL Vial	Sep. 18, 2025	Dec.19, 2025

^{*}Please note that the stockout date may vary by region, please check your local distribution centre for availability.

To help mitigate the shortage, Health Canada has approved the importation and release of **Fresenius Kabi's US-Authorized Acyclovir Injection**, **USP 500 mg per 10 mL (50 mg per mL)**.

Fresenius Kabi Product Code	NEW! MSD Product Code	McKesson Product Code	Product Description
622010	1000848	201602	Fresenius Kabi's US-Authorized Acyclovir Injection, USP 500 mg per 10 mL (50 mg per mL)

This product is available at all distribution centres and to all customers without restrictions.

We recognize the difficulties and inconvenience that you may encounter as a result of our supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

Joseph Le

Associate Director, IV Drugs joseph.le@fresenius-kabi.com

